



Press Release

02 July 2004

Uppsala, Sweden

Gyros appoints Jan Würtz as Chief Executive Officer

Gyros AB announced today the appointment of Mr. Jan Würtz as President and Chief Executive Officer within the company. Mr. Würtz has extensive executive experience gained within the Life Science industry and the diagnostics sector in particular.

Mr. Würtz has over 20 years experience in the Life Science industry, beginning at Gambro Engström AB, where he was appointed Vice President, Marketing and Sales. Since then, Mr. Würtz has held several senior management positions within Pharmacia Biosystems AB, Kabi Pharmacia AB and Pharmacia Diagnostics AB, where he was President and Chief Executive Officer, before joining Decim AB as President and Chief Executive Officer.

During his career, Mr. Würtz has held key roles in several mergers and acquisitions and has a proven track record for implementing restructuring and change programs that focus on revenue growth and profitability.

Mr. Würtz joins Gyros after working most recently as a consultant, focusing on executive management support, Director of Board engagements and venture capital projects.

Commenting on his new appointment, Mr. Würtz said, "This is a very exciting time to be joining Gyros. The company has a very solid technology platform and products that are performing well in the marketplace. Gyros is now entering a new phase, in which we need to build on the current foundation and ensure the long-term commercial success of the company."

About Gyros AB

Gyros miniaturizes and integrates laboratory applications, enabling scientists to generate more information from less sample and to improve lab performance. Using our proprietary technology platform, we increase productivity by streamlining the many steps of conventional applications into single, nanoliter scale procedures. Optimal environments are created for each application.

A Gyrolab microlaboratory, in the form of a compact disk, can process hundreds of samples in parallel, under the control of Gyrolab Workstation.

Our company will realize the full potential of the Gyros technology platform in the fields of drug discovery and diagnostics. Initial product offerings are focused towards the growing area of proteomics. Gyros has 75 employees working at its headquarters in Uppsala Science Park, Sweden and in sales offices in the USA and Europe.

For further information, visit www.gyros.com or contact:

Jan Würtz, President and CEO, Gyros AB

Tel: +46 (0)18 566 400

Mobile: +46 (0)70 592 5670

Email: jan.wurtz@gyros.com

Camilla Huse Bondesson, Vice President, Marketing and Sales, Gyros AB

Tel: +46 (0)18 566 384

Mobile: +46 (0)70 666 8209

Email: camilla.huse.bondesson@gyros.com

Statements in this press release that are not strictly historical may be forward-looking and include risks and uncertainties. Therefore, though based on Gyros' current expectations, it should be duly noted that a variety of factors could cause actual results and experiences to differ materially from what is herein expressed. Risks and uncertainties include, but are not limited to, risks associated with the management of growth and international operations (including effects of currency fluctuations), variability of operating results, unforeseen changes in the diagnostic and pharmaceutical markets, market competition, rapid or unexpected changes in technologies, fluctuations in product demand, difficulties to successfully develop, adapt, produce or commercialize products, the ability to identify and develop new products and to differentiate products from those of competitors, as well as various legal hazards.

Gyros, Gyrolab and the Gyros logo are registered trademarks of Gyros AB.